Article Overview

All products showcased on WIRED are meticulously and independently chosen by our editorial team. Nevertheless, we might obtain compensation from retailers and/or from product purchases made via these links. For more information, please refer to relevant details.

The Promise of Crispr Gene - editing Technology

In recent years, Crispr gene - editing technology has manifested its revolutionary potential. It has been harnessed for diverse applications, such as treating rare diseases, enabling crops to endure the harsh impacts of climate change, and even modifying the color of a spider's web. However, its most significant aspiration lies in contributing to the discovery of a cure for global diseases, like diabetes. A recent study has set its sights in this direction.

The Experiment on Type 1 Diabetes

• Patient Background: Type 1 diabetes is an autoimmune disorder affecting approximately 9.5 million people globally. In this condition, the immune system attacks the insulin - producing cells in the pancreas. Without insulin, the body loses its ability to regulate blood sugar. Failure to manage glucose levels, typically through insulin injections, can lead to nerve and organ damage, especially in the heart, kidneys, and eyes.

• Experimental Procedure: For the first time, researchers successfully implanted Crispr - edited pancreatic cells into a man with type 1 diabetes. Pancreatic islet cells were sourced from a non - diabetic deceased donor. These cells were then modified using the Crispr - Cas12b gene - editing technique to make them "hypoimmune," as explained by Sonja Schrepfer, a professor at Cedars - Sinai Medical Center in California and a scientific co - founder of Sana Biotechnology, the company behind this treatment. The edited cells were implanted into the patient's forearm muscle.

• Results: After 12 weeks, no signs of rejection were detected. Sana Biotechnology's subsequent report indicated that the implanted cells were still evading the patient's immune system after six months. Tests confirmed the functionality of the cells: they secreted insulin in response to glucose levels, a crucial step towards diabetes control without insulin injections. During patient follow - ups, four adverse events were recorded, but none were severe or directly associated with the modified cells.

Future Aspirations

The researchers' long - term objective is to apply immune - camouflaging gene edits to stem cells. Stem cells have the remarkable ability to reproduce and differentiate into other cell types within the body. By engineering hypoimmune stem cells, when they proliferate and generate new cells, these new cells will also be hypoimmune, as Schrepfer elaborated in a Cedars - Sinai Q + A earlier this year.

Traditional Transplant Challenges vs. New Approach

Historically, transplanting foreign cells into patients necessitated suppressing the patient's immune system to prevent rejection. This approach, however, entails substantial risks, including infections, toxicity, and long - term complications. As Schrepfer told Cedars - Sinai, witnessing patients succumbing to rejection or severe immunosuppression - related complications was disheartening, prompting her to focus on developing strategies to overcome immune rejection without immunosuppressive drugs.

Limitations and Future Outlook

• Study Limitations: While this research represents a milestone in the quest for type 1 diabetes treatments, it's essential to note that the study involved only one participant, who received a low dose of cells for a brief period. This was insufficient for the patient to discontinue insulin injections for blood sugar control. Additionally, an editorial in the journal Nature pointed out that some independent research groups failed to verify Sana's claim that their method endows edited cells with immune - evading capabilities.

• Future Plans: Sana intends to initiate more clinical trials starting next year. Despite the criticisms and limitations of the current study, the concept of transplanting immune - invisible cells holds great promise in the field of regenerative medicine.

This story originally emerged on WIRED en Español and has been translated from Spanish.